Sponsor
Hoffmann-La Roche
Clinical research sponsor
Clinical trials
60 shownA Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's DiseaseNCT07717411 · lead sponsor · 2026-11-30
RECRUITINGA Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or ObesityNCT07843498 · lead sponsor · 2026-09-30
RECRUITINGA Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular DiseaseNCT07843472 · lead sponsor · 2026-09-30
RECRUITINGNon-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple SclerosisNCT07827586 · lead sponsor · 2026-09-30
RECRUITINGA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)NCT07541170 · lead sponsor · 2026-09-30
RECRUITINGA Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 DiabetesNCT07843485 · lead sponsor · 2026-09-30
RECRUITINGA Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 DiabetesNCT07670416 · lead sponsor · 2026-07-03
RECRUITINGA Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic RetinopathyNCT07588100 · lead sponsor · 2026-06-18
RECRUITINGAn Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid ArthritisNCT07620392 · lead sponsor · 2026-06-03
RECRUITINGRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveNCT07413939 · lead sponsor · 2026-05-21
RECRUITINGA Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerNCT07405801 · lead sponsor · 2026-04-07
RECRUITINGA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058 · lead sponsor · 2026-03-23
RECRUITINGA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045 · lead sponsor · 2026-03-16
RECRUITINGA Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerNCT07287150 · lead sponsor · 2026-03-11
RECRUITINGA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)NCT07282574 · lead sponsor · 2026-03-10
RECRUITINGA Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment DecentralizationNCT07527741 · lead sponsor · 2026-02-23
RECRUITINGTo Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast CancerNCT07368998 · lead sponsor · 2026-02-18
RECRUITINGA Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast CancerNCT07347600 · lead sponsor · 2026-01-21
RECRUITINGA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)NCT07137598 · lead sponsor · 2025-12-05
RECRUITINGA Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseaseNCT07174310 · lead sponsor · 2025-11-24
RECRUITINGA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06793215 · lead sponsor · 2025-10-24
RECRUITINGA Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)NCT07161258 · lead sponsor · 2025-10-06
RECRUITINGA Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerNCT07054190 · lead sponsor · 2025-09-09
RECRUITINGA Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical PracticeNCT07284121 · lead sponsor · 2025-07-15
RECRUITINGScreening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesNCT07177352 · lead sponsor · 2025-07-02
RECRUITINGReal World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant TherapyNCT06862869 · lead sponsor · 2025-04-30
RECRUITINGClinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes MellitusNCT06704672 · lead sponsor · 2025-04-14
RECRUITINGA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerNCT06790693 · lead sponsor · 2025-04-09
RECRUITINGAn Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab TreatmentNCT06675955 · lead sponsor · 2024-12-13
RECRUITINGA Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)NCT06780150 · lead sponsor · 2024-09-26
RECRUITINGA Study to Investigate Mechanisms of Resistance to Breast Cancer TherapiesNCT06274515 · lead sponsor · 2024-04-02
RECRUITINGA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerNCT05894239 · lead sponsor · 2023-09-08
RECRUITINGA Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C MutationNCT05789082 · lead sponsor · 2023-06-20
RECRUITINGA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyNCT05646862 · lead sponsor · 2023-06-07
RECRUITINGA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerNCT04802759 · lead sponsor · 2021-06-22
RECRUITINGA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerNCT03424005 · lead sponsor · 2018-03-30
RECRUITINGA Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple SclerosisNCT07749157 · lead sponsor · 2026-11-23
NOT_YET_RECRUITINGStudy to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's DiseaseNCT07781657 · lead sponsor · 2026-10-31
NOT_YET_RECRUITINGA Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During TreatmentNCT07827573 · lead sponsor · 2026-10-30
NOT_YET_RECRUITINGA Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)NCT07503340 · lead sponsor · 2026-10-30
NOT_YET_RECRUITINGA Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesNCT07748208 · lead sponsor · 2026-10-30
NOT_YET_RECRUITINGA Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary DiseaseNCT07822334 · lead sponsor · 2026-10-20
NOT_YET_RECRUITINGA Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or OverweightNCT07589686 · lead sponsor · 2026-09-30
NOT_YET_RECRUITINGStudy to Test Effects and Safety of RO7568282 in Early Parkinson's DiseaseNCT07781644 · lead sponsor · 2026-09-30
NOT_YET_RECRUITINGA COPD Data Registry for Participants With Frequent ExacerbationsNCT07059273 · lead sponsor · 2026-09-14
WITHDRAWNA Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or OverweightNCT07499050 · lead sponsor · 2026-03-30
ACTIVE_NOT_RECRUITINGA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)NCT07234942 · lead sponsor · 2026-01-27
ACTIVE_NOT_RECRUITINGA Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)NCT07074886 · lead sponsor · 2025-11-13
ACTIVE_NOT_RECRUITINGA Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseNCT07170150 · lead sponsor · 2025-11-12
ACTIVE_NOT_RECRUITINGA Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or ObesityNCT07137585 · lead sponsor · 2025-09-30
ACTIVE_NOT_RECRUITINGA Study of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseNCT07169578 · lead sponsor · 2025-09-17
ACTIVE_NOT_RECRUITINGA Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 DiabetesNCT07112872 · lead sponsor · 2025-08-19
ACTIVE_NOT_RECRUITINGA Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityNCT07081958 · lead sponsor · 2025-07-29
COMPLETEDA Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple SclerosisNCT07483450 · lead sponsor · 2025-07-04
ACTIVE_NOT_RECRUITINGA Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult ParticipantsNCT06982131 · lead sponsor · 2025-06-04
ACTIVE_NOT_RECRUITINGA Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related ComorbidityNCT06965413 · lead sponsor · 2025-05-05
ACTIVE_NOT_RECRUITINGA Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple SclerosisNCT07667322 · lead sponsor · 2024-12-17
ACTIVE_NOT_RECRUITINGA Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)NCT06624059 · lead sponsor · 2024-11-18
COMPLETEDStudy to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple SclerosisNCT05949580 · lead sponsor · 2024-10-21
SUSPENDEDA Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung CancerNCT06497556 · lead sponsor · 2024-09-23
ACTIVE_NOT_RECRUITINGSponsor roles
lead sponsor830
collaborator190
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.